Due to an acute shortage of baby formula in Gaza, term and preterm infants that cannot be (fully) breastfed are facing an acute risk of severe malnutrition.
A group of doctors, including colleagues based in Israel and the U.S., are working to supply Nasser Hospital, one of the few facilities still providing neonatal care. These colleagues have asked us to share their donation link to help raise awareness and support this humanitarian effort.
In addition, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) is approaching nutrition companies to explore further ways to assist.
Since the campaign was launched, the project has already raised approximately 1,000 euros from European donors. In addition, the organizers have successfully secured a special discount on baby formula from Abbott-Israel, significantly increasing the impact of the funds raised.
EAP has been informed that the first shipment of formula has reached the WHO warehouse in Jerusalem on 3 August and is being transported to Gaza hospitals.
If you wish to help, your donation can make a real difference.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.